An Open-label, Non-randomized, Multicenter, Two Stage Designed Phase II Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms AXIPAN
- 24 Jul 2017 Status changed from active, no longer recruiting to completed.
- 16 May 2017 Results presented at the 112th Annual Meeting of the American Urological Association
- 21 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.